Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 and AK117 in Advanced Malignant Tumors
NCT05214482Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jan 2022
- Primary completion
- Nov 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, ligufalimab in cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), sponsored by Akeso, Inc.. Started Jan 2022; status: completed.
02
Drugs
ivonescimabligufalimab
03
Conditions
cancergastric adenocarcinomagastroesophageal junction adenocarcinomabiliary tract cancer (BTC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05214482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214482.